• Advanced HCC (BCLC stage C) with diagnosis confirmed pathologically or clinically

• Disease amenable to TACE

• No prior systemic therapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC

• Child-Pugh class A

• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1

• Life expectancy of at least 3 months

• At least one measurable intrahepatic lesion

• Adequate organ and hematologic function

• Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA\<10\^2 IU/mL

• Patients with hepatitis C need to finish the anti-HCV treatment